Would you rather run 2 separate trials, a phase 2 and then a phase 3, or run one pivotal ph2/3? The fda has already cleared them to do this for 2 new indications with unmet needs. I haven’t seen this happen before. I’m guessing you have? The way I see it, as a long investor here, this is a very positive development which should cut out 18-36 months of development time and save the company millions of dollars. I’m all for anything that shortens development time and saves cash.
I know the original poster suggested skipping ph2, and jumping right to a ph3. I responded because Anavex is doing the next best possible thing, running 1 trial to get approval which I think was the point of the original poster.
Market Data 
Markets 
AI
